Normal
23rd-24th June 2022

5th Annual MarketsAndMarkets Next-Gen Immuno-Oncology Conference

Hyatt Regency Boston/Cambridge

Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 23rd-24th, June 2022, in Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy  

Co-Related Conferences
WHAT TO EXPECT

Key Highlights

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses

Who Should Attend?

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

Why Attend?

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA
New Antibody Formats & Adoptive Cell Therapy
End of Day 1 followed by Drinks, Reception and Networking
New Immune Checkpoints, Biomarker and Tumour Microenvironment
CONFERENCE SPEAKERS
Speakers
Lokesh Agrawal
Lokesh Agrawal
Program Director, Biorepositories and Biospecimen Research Branch (BBRB), , NIH
Colin Brenan
Colin Brenan
CEO, Kibur Medical Inc.
Bradlee Heckmann
Bradlee Heckmann
CSO, Asha Therapeutics
Ian Pike
Ian Pike
Chief Scientific Officer, Proteome Sciences PLC
Jessica McDonough
Jessica McDonough
Co-Founder, Attivare Therapeutics
Roxana Schillaci
Roxana Schillaci
Principal Researcher, Argentina National Council of Scientific Research
Sam Shrivastava
Sam Shrivastava
CEO, Founder, Asha Therapeutics
Jennifer Elliott
Jennifer Elliott
Senior Director, Oncology & Precision Medicine , Qiagen
SPONSORS
Gold
example-image

Proteome Sciences

example-image

Sanyou Bio

Silver
example-image

Larvol

example-image

PHC Group

example-image

Epredia

example-image

Angle Plc

Bronze
example-image

EpigenDx

Speaking Partner
example-image

PromoCell

example-image

TransCure bioServices

example-image

QIAGEN

example-image

Kiromic Biopharma

example-image

Veracyte

example-image

Kibur Medical

Exhibition Partner
example-image

BioVT

example-image

iCura Diagnostics

Meeting Partner
example-image

Talem Therapeutics

PARTNERS
Media Partners
example-image

Bentham Science

LOCATION
Hyatt Regency Boston/Cambridge
About the Hotel

PAST EVENT GALLERY